Compare · CCEL vs PGNY
CCEL vs PGNY
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $2.02B, about 24.3x CCEL ($83.3M).
- Over the past year, CCEL is down 36.3% and PGNY is up 15.1% - PGNY leads by 51.3 points.
- PGNY has been more active in the news (25 items in the past 4 weeks vs 1 for CCEL).
- PGNY has more recent analyst coverage (25 ratings vs 0 for CCEL).
- Company
- Cryo-Cell International Inc.
- Progyny Inc.
- Price
- $3.41-1.16%
- $25.80-0.58%
- Market cap
- $83.3M
- $2.02B
- 1M return
- -2.85%
- +8.81%
- 1Y return
- -36.26%
- +15.08%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2019
- News (4w)
- 1
- 25
- Recent ratings
- 0
- 25
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest CCEL
- VP Finance, CFO Taymans Jill M exercised 7,500 shares at a strike of $3.10, increasing direct ownership by 17% to 52,896 units (SEC Form 4)
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives Acceptance of Compliance Plan From NYSE American
- Cryo-Cell International Receives FACT Re-accreditation, Setting the Longest Independently Validated Quality Track Record Among U.S. Private Cord Blood Banks
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
- SEC Form 10-K filed by Cryo-Cell International Inc.
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
Latest PGNY
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 1,421 shares and sold $64,184 worth of shares (2,517 units at $25.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 74,688 units (SEC Form 4) (tax withholding)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,015 shares and sold $45,022 worth of shares (1,798 units at $25.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 82,378 units (SEC Form 4) (for withholding tax)
- CHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 811,472 units (SEC Form 4) to satisfy tax liability
- CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)
- Director Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)
- Chief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)
- EVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares and sold $61,053 worth of shares (2,398 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 85,191 units (SEC Form 4) to cover withholding tax
- Director Gordon Kevin K sold $137,445 worth of shares (5,500 units at $24.99), disposed of 2,526 shares and acquired 2,526 shares, decreasing direct ownership by 54% to 6,792 units (SEC Form 4)
- New Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare System